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Abstract: Many drugs of abuse signal through receptors that
couple to G proteins (GPCRs), so the factors that control GPCR
signaling are likely to be important to the understanding of drug
abuse. Contributions by the recently identified protein family,
regulators of G protein signaling (RGS) to the control of GPCR
function are just beginning to be understood. RGS proteins can
accelerate the deactivation of G proteins by 1000-fold and in cell
systems they profoundly inhibit signaling by many receptors,
including mu-opioid receptors. Coupled with the known dynamic
regulation of RGS protein expression and function, they are of
obvious interest in understanding tolerance and dependence
mechanisms. Furthermore, drugs that could inhibit their activity
could be useful in preventing the development of or in treating
drug dependence.
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Cell)cell communication is fundamental to brain function
and the G-protein-coupled receptor (GPCR) superfamily (1)
is one of most abundant and diverse protein families in the
central nervous system (CNS). In the human genome there
are 616 GPCRs, excluding olfactory receptors, with only the
ribosomal proteins being more numerous (2). The guanine
nucleotide binding proteins (G proteins), which act down-
stream of the GPCRs, perform crucial functions in the
regulation of neural processes. They are critical signaling
elements for drugs of abuse, such as opioids, and dopamine-
modulating drugs, such as cocaine and amphetamine. A
tremendous amount of structural and mechanistic infor-
mation is known about GPCR signaling (3). The G protein
consists of alpha and beta-gamma subunits, which under-
go interlocking kinetic cycles of nucleotide binding,
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hydrolysis, and release interacting with subunit association
and dissociation (4). Thus, G-protein function is intrinsic-
ally kinetic. The recent identification of the novel family of
regulators of G protein signaling, or RGS proteins (5–7),
provided emphatic confirmation of the role of kinetics in
G-protein function.
RGS proteins were identified genetically in 1996 by their
ability to reduce signaling by G proteins in yeast (Sac-
charomyces cervesiae) (8) and Caenorhabditis elegans (9).
The main mechanism of RGS-mediated inhibition of
G-protein signaling is through RGS binding to the Ga
subunit and acting as a GTPase accelerating protein (GAP)
to rapidly deactivate Ga. RGS proteins may also competit-
ively inhibit Ga binding to effectors such as phospholipase
C (10). There are at least 30 members of the RGS protein
family (11). The majority of RGS proteins interact with
either Gi or Gq family G proteins and influence cAMP,
Ca2+, MAP kinase, or ion channel signaling, however, RGS
proteins that bind Ga12/13 (12,13) and Gas (14) have also
recently been identified. There is strong evidence implica-
ting RGS proteins in the subsecond kinetics of Gi- and
Go-mediated ion channel activation and deactivation in
neurons (15,16). More recently, the conserved RGS protein
domain has been found to serve as a multifunctional pro-
tein adapter which can recruit many effectors or regulators
to the vicinity of activated G proteins (for reviews see Refs
6,7,17). Notable examples include P115rhoGEF (12), the A
kinase anchoring protein d-AKAP2 (18) and GRK2 (19).
One other intriguing aspect of RGS proteins is that they
undergo rather profound regulation of expression by signal
transduction events. This makes them uniquely well-suited
to play a role in the cellular changes that underlie tolerance
and/or dependence that are the hallmarks of drugs of abuse.
Indeed, Burchett et al. (20) demonstrated amphetamine-
induced upregulation of RGS2 and -3 with chronic admin-
istration, whereas RGS5 was upregulated only by acute
amphetamine. Similarly, stimulation of both mu and delta
opioid receptors induced RGS4 upregulation in PC12 cells
expressing those receptors (21).
There is a wealth of information about the effects of RGS
proteins on G proteins in vitro and in overexpression
studies in transfected mammalian cells in which different
RGS proteins modulate signaling (6,7,22). In general,
expression of RGS proteins that target Gi, Go, and Gq
reduces signaling by those G proteins. The specificity of
different RGS proteins in vitro is fairly well established
though it appears that specificity in intact tissues or in
differentiated cell types may be greater than predicted by
the RGS-Ga specificity alone (11). In particular, there is
evidence for receptor-specific effects of RGS proteins in
pancreatic acinar cells (23) and in vascular smooth muscle
(24). Such specificity has not been established in CNS sys-
tems but it is likely that similar observations will be made
in neurons. More recently, evidence of differential RGS
effects on opioid signaling to different effectors has been
found (M.J. Clark et al., manuscript submitted).
Approaches to Studying the Function
of Endogenous RGS Proteins
A major limitation of current knowledge is that the phy-
siological functions of RGS proteins remain very poorly
defined. Only two RGS knockouts have been reported,
RGS9 in the eye and RGS2 (25,26). The RGS9 knockout
shows dramatically slowed visual potentials (25) and the
RGS2 knockout has subtle behavioral and immunologic
phenotypes (26). The phenotype of the RGS9 knockout with
respect to CNS function, behavior, and drug abuse has not
yet been reported and will be of significant interest. One
difficulty in unraveling the function of RGS proteins has
been the many subtypes of both G proteins and RGS pro-
teins which may render some functions redundant. This
limits an understanding of their function in vivo using
standard antisense or knockout strategies.
To determine the contribution of RGS proteins as a group
to biological responses mediated by Go and Gi, we have
taken advantage of a point mutation in the Ga subunit that
abrogates the RGS–Ga protein interaction (27). This glycine
to serine mutation in the switch 1 region of the yeast Ga
subunit renders it insensitive to inhibition by the yeast
RGS (28). We characterized the mammalian homologs
(G184S in ao and G183S in Gai1) and found that they pre-
vent the GAP activity of RGS4 and RGS7 and block RGS4
binding to aluminum fluoride-activated Ga subunits. The
mutation does not affect other functions of the Ga subunit
(29) such as: the intrinsic GTPase activity of the G protein
or its coupling to bc subunits, receptors, or effectors
(adenylyl cyclase). Thus, the only known effect of the Go
G184S and Gai1 G183S mutation is to prevent RGS action
on G. Based on this mechanism, one would expect that both
the inhibitory GAP activity and potential effector functions
of any RGS at that Ga subunit would be blocked by this
mutation.
Recent publications from the Ikeda and Lambert labor-
atories (30,31) demonstrate profound changes in response
kinetics and sensitivity in neurons expressing Ga subunits
with these RGS-insensitive mutations. Furthermore, studies
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with mu opioid receptors show that the G184S mutant of
Gao dramatically enhances morphine-induced inhibition of
adenylyl cyclase in C6 glioma cells (M.J. Clark et al.,
manuscript submitted). A 5-fold increase in maximal
adenylyl cyclase inhibition and an 8-fold reduction in EC50
was seen. This shows that endogenous RGS proteins in C6
glioma cells have a profound effect on opioid signaling, and
elimination of the RGS action (such as by an RGS inhibitor
drug) could dramatically potentiate opioid responses. This
could lead to enhanced analgesic responses without leading
to tolerance and dependence. This is possible because opi-
oid tolerance depends in part on the GRK/b-arrestin-medi-
ated receptor desensitization which occurs at very high
receptor occupancy. If an RGS inhibitor could permit opioid
analgesia to be produced by low agonist doses, which only
occupy a small fraction of receptors, tolerance, and possibly
dependence, could be avoided. This scenario of combining
an agonist drug with an agent enhancing its function is
similar to the use of the aromatic amino acid decarboxylase
inhibitor carbidopa with l-Dopa to permit lower doses to be
used and to direct signaling to the tissue of interest (i.e.
CNS vs. peripheral tissues). The combination of an RGS
inhibitor with an opioid agonist would permit lower doses
of opioid to be used, which might reduce tolerance and may
also enhance signaling in selected brain regions if the RGS
proteins important in those regions could be targeted by an
inhibitor. Two preliminary reports have described RGS
inhibitor peptides with micromolar potency (32,33). Further
developments in this area are eagerly awaited.
Studies with the RGS-insensitive Ga subunits should
provide a broad-brush view of RGS actions at a particular
Ga subunit. A more targeted approach to deciding which
RGS protein is mediating a particular function is also
required. Ribozymes are unique RNA enzymes that can
recognize and cleave other RNA molecules in a sequence-
specific fashion (34). They were initially used to inhibit
gene expression in HIV virus (35) and cancer (36). Compared
with the antisense oligos, ribozymes offer significant
advantages: (i) they operate as site-specific ribonucleases,
resulting in catalytical cleavage of the target mRNAs; (ii);
they are more stringent than antisense oligos in binding
mRNA targets; (iii) controls for ribozyme activity can be
made by substituting nucleotides in the catalytic core to
produce an inactive ribozyme (37). Among the several types
of ribozymes, the hammerhead ribozymes are the most
extensively characterized with enhanced catalytic turnover
and stability (38). They cleave 3¢ to a GUC sequence motif
in the target mRNA (38). Wang et al. (24) recently demon-
strated that chemically synthesized ribozymes targeted
against specific RGS proteins can be used to knock-down
their expression in vascular smooth muscle cells. Interest-
ingly, the RGS3-ribozyme selectively enhanced M3
muscarinic responses, whereas the RGS5-ribozyme selec-
tively enhanced angiotensin II responses. Using the related
antisense oligodeoxynucleotide approach, Garzon et al. (39)
showed that an RGS9 antisense construct injected i.c.v.
produced an enhanced opioid analgesic effect with mor-
phine and beta-endorphin, whereas an RGS2 antisense
reduced the opioid effects. In contrast, Potenza et al. (40)
found that overexpression of RGS2 inhibited opioid
responses in a melanophore response system – an effect
opposite to that predicted by the Garzon results. Thus,
additional study is clearly needed to better define the role of
RGS proteins, in general, and RGS2, -4, and -9 in particular,
in both the acute actions and long-term regulation of opioid
signaling. Similar approaches should also be relevant in
studies of other drugs of abuse.
Tools Needed to Advance the Study
of RGS Protein Physiology
A better understanding of the in vivo physiology and
pharmacology of the RGS protein family is important for a
full understanding of drug abuse. A number of limitations
have slowed the pace of research in the RGS field. First,
studies of the expression of RGS protein have been largely
limited to assessments at the mRNA level. RGS proteins
are often expressed at low levels and many antibodies are
not specific enough to detect them in Western blots of
complex tissues. Thus, good antibodies to identify the
location and regulation of RGS at the protein level are
important. Second, experimental approaches to selectively
block RGS protein function (knockouts, ribozymes, RNAi,
chemical inhibitors) need to be developed to dissect the
roles of specific RGS proteins. The availability of specific
chemical inhibitors is also the first step toward the devel-
opment of RGS inhibitor drugs. Third, is the need for good
assays to permit rapid screens for potent RGS inhibitors.
The gold standard assays for RGS function are complex
single-turnover [32P]GTPase assays that are not amenable
to high-throughput approaches. Improved and simplified
assays for RGS function are needed. Finally, creative
approaches to dissect the roles and interactions among RGS
and non-RGS domains will be essential to fully understand
the biological roles of RGS proteins. This article has
focused on the GAP activity of the RGS domains but the
RGS domains are also scaffolds to permit assembly and
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regulation of the other diverse signal transduction modules
found in RGS proteins.
Future Prospects and Key Questions
As noted above, the potential for RGS proteins as drug
targets is substantial but completely unexploited. To
develop this potential fully many questions need to be
answered. What are the distribution, regulation, and role of
the more than 30 endogenous RGS proteins in receptor
signaling? What determines the specificity of RGS proteins
for different receptor responses and what are the functions
of the N- and C-terminal non-RGS modules? What is the
role of RGS proteins in drug tolerance and dependence? Can
RGS inhibitors prevent or reverse tolerance and/or
dependence (perhaps by permitting the use of lower doses of
drugs, e.g. opiates)? The RGS protein family thus provides
fertile ground for additional study in drug abuse.
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